Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Carisma Therapeutics Inc.
CARMCurrent price
0.97 USD
-0.017 USD (-1.70%)
Last closed
1 USD
Company
–
ISIN
US14216R1014
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
41 960 448 USD
Yield for 12 month
-63.28 %
1Y
3Y
5Y
10Y
15Y
CARM
Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania. Address: 3675 Market Street, Philadelphia, PA, United States, 19104
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
11 USDP/E ratio
–Dividend Yield
–Current Year
+14 919 000 USD
Last Year
+9 834 000 USD
Current Quarter
+3 385 000 USD
Last Quarter
+9 197 000 USD
Current Year
+6 654 000 USD
Last Year
+3 744 000 USD
Current Quarter
+3 385 000 USD
Last Quarter
+8 942 000 USD
Key Figures CARM
1 year
3 years
5 years
10 years
EBITDA
-63 367 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-56.08 %
PEG Ratio
–
Return On Equity TTM
-362.79 %
Wall Street Target Price
11 USD
Revenue TTM
20 268 000 USD
Book Value
-0.27 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-11.6 %
Dividend Yield
–
Gross Profit TTM
–
Earnings per share
-1.65 USD
Diluted Eps TTM
-1.65 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics CARM
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
-1 %Dividend History CARM
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:20
Payout Ratio
–
Last Split Date
08.03.2023
Dividend Date
08.03.2023
Stock Valuation CARM
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
0.4716
Price Sales TTM
2.0703
Enterprise Value EBITDA
-0.0615
Price Book MRQ
116.5567
Financials CARM
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators CARM
For 52 weeks
0.8 USD
3.16 USD
50 Day MA
0.99 USD
Shares Short Prior Month
1 104 654
200 Day MA
1.48 USD
Short Ratio
10.74
Shares Short
1 045 768
Short Percent
3.14 %
BeatStart